Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. Τα αντισώματα ανοσίας έχουν αποδειχθεί 1 εβδομάδα μετά τον κύριο εμβολιασμό για ρινοτραχειίτιδα, καλυκοϊό και συστατικά chlamydophila felis. Η διάρκεια της ανοσίας είναι 1 έτος μετά τον τελευταίο (επαν) εμβολιασμό.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. Οι αντιδράσεις ανοσίας έχουν αποδειχθεί μία εβδομάδα μετά την αρχική πορεία εμβολιασμού για ρινοτραχειίτιδα, καλυκοϊό, συστατικά chlamydophila felis και παγκρεακοπενία. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

statens serum institut, denmark (0000005700) artillerivej 5,, dk-2300 copenhagen s - poliovirus vaccine; poliovirus vaccine; poliovirus vaccine - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ - 8000034777 poliovirus vaccine 40.000000 du; 8000034777 poliovirus vaccine 8.000000 du; 8000034777 poliovirus vaccine 32.000000 du - poliomyelitis, trivalent, inactivated, whole virus

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

aj vaccines a/s, denmark artillerivej 5, dk-2300 copenhagen s +45 7229 7000 - poliovirus vaccine; poliovirus vaccine; poliovirus vaccine - inj.so.pfs (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - poliovirus vaccine 40du; poliovirus vaccine 8du; poliovirus vaccine 32du - poliomyelitis, trivalent, inactivated, whole virus

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - (αιμοσυγκολλητίνη και νευραμινιδάση) του στελέχους Α / Βιετνάμ / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - Εμβόλια - Ενεργός ανοσοποίηση έναντι του υποτύπου h5n1 του ιού της γρίπης Α. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - Εμβόλια - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - Εμβόλια - active immunisation against h5 subtype of influenza a virus.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

aj vaccines a/s, denmark artillerivej 5, dk-2300 copenhagen s +45 7229 7000 - mycobacterium bovis (bcg) danish strain 1331 - ps.inj.sus (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 2-8x10 6 cfu/ml - mycobacterium bovis (bcg) danish strain 1331 0ml - tuberculosis, live attenuated

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

bilthoven biologicals b.v. (0000012092) antonie van leeuwenhoeklaan 9-13, ma bilthoven, 3721 - inactivated poliomyelitis vaccine type 1(mahoney); inactivated poliomyelitis vaccine type 2(mef-1); inactivated poliomyelitis vaccine type 3(saukett) - suspension for injection - inactivated poliomyelitis vaccine type 1(mahoney) (8000003623) 40u; inactivated poliomyelitis vaccine type 2(mef-1) (8000003624) 8u; inactivated poliomyelitis vaccine type 3(saukett) (8000003626) 32u